首页> 美国卫生研究院文献>Neoplasia (New York N.Y.) >Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
【2h】

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.

机译:Hedgehog / Gli1在卵巢肿瘤细胞上转型调节FANCD2:其抑制诱导HR缺乏和协同致死性与PARP抑制。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ovarian cancer (OC) is one of the most lethal type of cancer in women due to a lack of effective targeted therapies and high rates of treatment resistance and disease recurrence. Recently Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown promise as chemotherapeutic agents; however, their efficacy is limited to a small fraction of patients with BRCA mutations. Here we show a novel function for the Hedgehog (Hh) transcription factor Glioma associated protein 1 (GLI1) in regulation of key Fanconi anemia (FA) gene, FANCD2 in OC cells. GLI1 inhibition in HR-proficient OC cells induces HR deficiency (BRCAness), replication stress and synergistic lethality when combined with PARP inhibition. Treatment of OC cells with combination of GLI1 and PARP inhibitors shows enhanced DNA damage, synergy in cytotoxicity, and strong in vivo anticancer responses.
机译:卵巢癌(OC)是由于缺乏有效的靶向疗法和高治疗抗性和疾病复发而导致女性中最致命的癌症类型之一。最近聚(ADP-核糖)聚合酶抑制剂(PARPI)表现为非化学治疗剂;然而,它们的功效仅限于BRCA突变的一小部分患者。在这里,我们显示刺猬(HH)转录因子胶质瘤相关蛋白1(GLI1)的新功能,调节关键的FANCONI贫血(FA)基因,FANCD2在OC细胞中。 GLI1在HR-Propiopion oc细胞中抑制诱导HR缺乏(BRCANESS),复制应力和协同致死致死的抑制。用Gli1和PARP抑制剂组合治疗OC细胞显示出增强的DNA损伤,细胞毒性协同效应,体内抗癌反应强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号